RxSight, Inc.
RXST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $139,927 | $89,077 | $49,005 | $22,593 |
| % Growth | 57.1% | 81.8% | 116.9% | – |
| Cost of Goods Sold | $40,984 | $35,312 | $27,677 | $18,076 |
| Gross Profit | $98,943 | $53,765 | $21,328 | $4,517 |
| % Margin | 70.7% | 60.4% | 43.5% | 20% |
| R&D Expenses | $34,367 | $29,051 | $25,981 | $24,499 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $101,434 | $74,799 | $58,665 | $32,805 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $135,801 | $103,850 | $84,646 | $57,304 |
| Operating Income | -$36,858 | -$50,085 | -$63,318 | -$52,787 |
| % Margin | -26.3% | -56.2% | -129.2% | -233.6% |
| Other Income/Exp. Net | $9,453 | $1,497 | -$3,429 | $4,107 |
| Pre-Tax Income | -$27,405 | -$48,588 | -$66,747 | -$48,680 |
| Tax Expense | $50 | $20 | $9 | $8 |
| Net Income | -$27,455 | -$48,608 | -$66,756 | -$48,688 |
| % Margin | -19.6% | -54.6% | -136.2% | -215.5% |
| EPS | -0.71 | -1.41 | -2.41 | -1.78 |
| % Growth | 49.6% | 41.5% | -35.4% | – |
| EPS Diluted | -0.71 | -1.41 | -2.41 | -1.78 |
| Weighted Avg Shares Out | 38,868 | 34,455 | 27,662 | 27,367 |
| Weighted Avg Shares Out Dil | 38,868 | 34,455 | 27,662 | 27,367 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,474 | $6,574 | $1,517 | $54 |
| Interest Expense | $21 | $3,308 | $4,946 | $3,682 |
| Depreciation & Amortization | $3,624 | $4,243 | $4,022 | $3,988 |
| EBITDA | -$23,760 | -$41,037 | -$57,779 | -$41,010 |
| % Margin | -17% | -46.1% | -117.9% | -181.5% |